Newsletter: December 2020

Facilities and Operations

GMP Inspection Completed by ANVISA at WuXi Biologics DS facility Read More

WuXi Biologics Launched Biologics Integrated Innovation Center in Hangzhou for next-generation biological products based on microbial fermentation and viral production Read More

WuXi Biologics Unveils New Process Development and Testing Facility in King of Prussia, Pennsylvania Read More

WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States (Cranbury, NJ) Read More

WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in Worcester, MA Read More

Resources

Continuous Biomanufacturing Implementation – Using an Intensified and Integrated Bioprocess Platform (White Paper)

Reducing Fill Risk in Drug Product Manufacture Utilizing New State-of-the-Art Systems and Platforms (Podcast)

Antibody Drug Conjugates (ADC) Drug Development and Manufacturing Trends, Challenges and Solutions (Webinar)

New Flexible Bispecific Antibody Format Demonstrates Improved Therapeutic Properties And Manufacturability (White Paper)

Scale-Out Biomanufacturing – A Paradigm Change to Scale-Up (White Paper)

Partner News

Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer Read More

Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation Read More

WuXi Biologics and AC Immune Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development Read More

WuXi Biologics and AB2 Bio Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa Read More

Awards and Achievements

WuXi Biologics standardizes a remarkable 12 month “DNA to IND” timeline through its streamlined development platform Read More